Mirae Asset Global Investments Co. Ltd. purchased a new stake in Chemed Corporation (NYSE:CHE – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,853 shares of the company’s stock, valued at approximately $936,000.
Several other large investors have also recently bought and sold shares of CHE. Vise Technologies Inc. lifted its position in Chemed by 45.9% during the third quarter. Vise Technologies Inc. now owns 2,022 shares of the company’s stock worth $1,021,000 after acquiring an additional 636 shares during the last quarter. North Dakota State Investment Board bought a new stake in shares of Chemed during the third quarter worth approximately $201,000. VestGen Advisors LLC acquired a new position in shares of Chemed in the third quarter valued at approximately $202,000. Oppenheimer & Co. Inc. grew its position in shares of Chemed by 0.3% in the third quarter. Oppenheimer & Co. Inc. now owns 14,568 shares of the company’s stock valued at $7,358,000 after purchasing an additional 47 shares during the last quarter. Finally, Signaturefd LLC grew its position in shares of Chemed by 28.3% in the third quarter. Signaturefd LLC now owns 367 shares of the company’s stock valued at $185,000 after purchasing an additional 81 shares during the last quarter. 95.85% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on CHE. Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and lifted their price target for the stock from $520.00 to $620.00 in a report on Wednesday, October 28th. Bank of America restated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer upped their price objective on Chemed from $590.00 to $625.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. UBS Group increased their price objective on Chemed from $650.00 to $675.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Finally, Royal Bank Of Canada lifted their target price on Chemed from $548.00 to $585.00 and gave the stock a “sector perform” rating in a report on Thursday, October 29th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $603.00.
Chemed Stock Down 0.3%
NYSE CHE opened at $526.43 on Monday. The company has a current ratio of 1.11, a quick ratio of 1.08 and a debt-to-equity ratio of 0.27. Chemed Corporation has a 1-year low of $365.20 and a 1-year high of $562.24. The company has a 50 day moving average of $514.46 and a 200-day moving average of $465.08. The company has a market cap of $6.85 billion, a price-to-earnings ratio of 25.19, a PEG ratio of 2.01 and a beta of 0.50.
Chemed (NYSE:CHE – Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.44 by $0.31. The business had revenue of $690.94 million for the quarter, compared to the consensus estimate of $685.04 million. Chemed had a return on equity of 35.18% and a net margin of 10.61%. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.27 earnings per share. On average, equities research analysts expect that Chemed Corporation will post 24.05 earnings per share for the current fiscal year.
Chemed Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, December 4th. Investors of record on Monday, November 16th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Monday, November 16th. Chemed’s payout ratio is 13.40%.
Insider Transactions at Chemed
In related news, CEO Kevin McNamara sold 2,000 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $537.90, for a total transaction of $1,075,800.00. Following the completion of the sale, the chief executive officer owned 82,220 shares of the company’s stock, valued at $44,226,138. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Spencer Lee sold 1,000 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the sale, the executive vice president owned 13,912 shares in the company, valued at $7,526,948.48. The trade was a 6.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 9,920 shares of company stock valued at $5,223,056. 3.33% of the stock is owned by insiders.
About Chemed
Chemed Corporation is a U.S.-based company operating through two principal businesses: VITAS Healthcare, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing, drain-cleaning and water-restoration services.
VITAS serves patients with serious illnesses through home-based care and services in hospice facilities and other care settings. Roto-Rooter serves residential and commercial customers with plumbing and drain services, as well as cleanup and restoration following water damage.
Chemed’s businesses operate across the United States.
See Also
- Five stocks we like better than Chemed
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
